A Look Into AstraZeneca’s Debt
Over the past three months, shares of AstraZeneca Inc. (NASDAQ:AZN) decreased by 4.43%. When understanding a companies price…
AstraZenceca’s Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement…
AstraZeneca’s Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
In a trial, lung cancer patients treated with AstraZeneca plc’s (NASDAQ:AZN) immunotherapy Imfinzi (durvalumab) pre- and post-surgery lived significantly longer without the…
AstraZeneca Announces TAGRISSO Demonstrated Statistically And Clinically Meaningful Improvement In Overall Survival
Positive high-level results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival
AstraZeneca Announced Earlier: Imfinzi improved Event-free Survival In Resectable Lung Cancer
Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo- controlled trial showed that treatment with AstraZeneca's Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvan
AstraZeneca Announced Enhertu Showed Clinically Meaningful And Durable Responses Across Multiple HER2-Expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients.
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
As previously announced, Valneva SE (NASDAQ:VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new…
Astrazeneca Announces Major Investment In Ontario’s Life Sciences Sector
Investment brings 500 scientific and high-tech jobs to the Greater Toronto Area
MISSISSAUGA, ON, Feb. 27, 2023 /CNW/ - AstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific
Astrazeneca’s Tablet Formulation Of Calquence (Acalabrutinib) Has Been Approved In The European Union (Eu) For Adult Patients With Chronic Lymphocytic Leukemia.
The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the ELEVATE-PLUS trials published in the American Society of
AstraZeneca And Merck Announced Results From The Final Analysis Of Overall Survival From Phase 3 Propel Trial Of Lynparza Plus Abiraterone And Prednisone Or Prednisolone (Abi/Pred), Compared To Placebo Plus Abi/Pred. Did Not Reach Statistical Significa…
Median OS was 42.1 months for the LYNPARZA plus abi/pred arm versus 34.7 months for the placebo plus abi/pred arm, representing a 7.4-month absolute difference in median OS versus a standard of care